Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
3
×
san francisco blog main
san francisco top stories
startups
3
×
vc
3
×
deals
ipo
san diego blog main
san diego top stories
accent therapeutics
acetylon pharmaceuticals
aducanumab
alzheimer's disease
amblyotech
ambys medicines
asklepios biopharmaceutical
azacitidine
beta-thalassemia
bioeurope
biogen
biomarin pharmaceutical
boston
boulder/denver blog main
boulder/denver top stories
brainvectis
c. greg guyer
cancer
cara therapeutics
cell therapy
constellation pharmaceuticals
dacogen
decitabine
deerfield management
What
medicines
new
3
×
biotech
developing
startup
activity
aiming
aims
ambys
approach
approvals
based
big
bio
biogen
called
clamped
control
covid
deadly
deal
debuted
debuts
delays
diseases
drugs
economic
epigenetic
epigenetics
fast
fda
field
flagship’s
formed
future
including
ipo
isn’t
launch
liver
Language
unset
Current search:
new
×
startups
×
photo
×
" new york top stories "
×
vc
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?